CLINICAL_TRIALS
trial_result
· 2011-04-20
Clinical Trial Update: Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia [Phase 2]
Summary
A Phase 2 study assessing the efficacy and safety of NBI-98854 in tardive dyskinesia has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 2 | Status: COMPLETED